美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

科興生物

6.47

0.0000

成交量：- -

成交額：- -

市值：3.89億

市盈率：-4.94

高：6.47

開：6.47

低：6.47

收：6.47

52周最高：6.47

52周最低：6.47

股本：6,006.07萬

流通股本：3,116.90萬

量比：0.52

換手率：- -

股息：- -

股息率：- -

每股收益(TTM):-1.3100

每股收益(LYR):1.06

淨資產收益率：25.15%

總資產收益率：11.46%

市淨率：0.52

市盈率(LYR):6.13

資料載入中...

總覽公司新聞資訊公告

國產甲肝疫苗獨家中標阿曼兩年訂單

科興流感疫苗在阿拉伯聯合酋長國獲批註冊

科興獲准維持納斯達克上市地位，需在5月11日前完成財報報送

納斯達克批准科興維持上市地位

科興生物董事會爭鬥再起波瀾退市危機依舊待解

Antigua法院發布臨時命令，授予科興生物董事會控制權，直至2025年股東大會爭議審判

科興生物：安提瓜法院發布臨時命令，授予董事會控制權直至爭議2025年股東大會審理結束

科興生物退市風暴：從「疫苗之王」到轟然坍塌

2025年中國生物製劑行業政策、產業鏈、市場規模、研發支出、競爭格局及未來發展趨勢研判：已成為醫藥行業增長最快的領域之一，市場規模將達到6752億元[圖]

科興生物陷退市危機，十年內鬥拖累經營與治理

停牌6年後科興生物要退市

国际金融报

科興生物再觸退市紅線治理困局拖累美股上市地位

华夏时报网

科興生物收到納斯達克退市通知；廣譽遠副總裁離任

21世纪经济报道

科興生物收到納斯達克退市通知公司回應：計劃進行聽證申辯會

每日经济新闻

科興生物人干擾素α1b吸入溶液納入突破性治療品種名單

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/SVA/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"SVA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVA\",,,,,undefined,":{"symbol":"SVA","market":"US","secType":"STK","nameCN":"科興生物","latestPrice":6.47,"timestamp":1774036800000,"preClose":6.47,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":31169000,"shares":60060702,"eps":-1.31,"marketStatus":"停牌","change":0,"latestTime":"03-23 08:22:42 EDT","open":6.47,"high":6.47,"low":6.47,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.31,"tradingStatus":1,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1774272600000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1102482000000,"exchange":"NASDAQ","adjPreClose":6.47,"volumeRatio":0.5219117885997689},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"SVA\",,,,,undefined,":{"symbol":"SVA","floatShares":31169000,"roa":"11.46%","roe":"25.15%","lyrEps":1.055174,"volumeRatio":0.5219117885997689,"shares":60060702,"dividePrice":0,"high":6.47,"amplitude":0,"preClose":6.47,"low":6.47,"week52Low":6.47,"pbRate":"0.52","week52High":6.47,"institutionHeld":0.1888,"latestPrice":6.47,"eps":-1.31,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.31,"open":6.47,"prevYearClose":6.47,"prevWeekClose":6.47,"prevMonthClose":6.47,"prevQuarterClose":6.47,"fiveDayClose":6.47,"twentyDayClose":6.47,"sixtyDayClose":6.47},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/SVA\",params:#limit:5,,,undefined,":[{"date":"2025-07-08","symbol":"SVA","amount":55,"announcedDate":"2025-04-01","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-05-23","defaultRemindTime":1751981400000,"name":"科兴生物","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-07","payableDate":"2025-05-23","currency":"USD","dateTimestamp":1751947200000,"payDate":"2025-07-07"},{"market":"US","date":"2022-04-29","symbol":"SVA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1651204800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-12-31","symbol":"SVA","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1640926800000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2021-09-17","symbol":"SVA","fiscalQuarterEnding":"2021/06","expectedEps":null,"name":null,"time":"盤後","type":"earning","dateTimestamp":1631851200000,"reportTimeType":"post","actualEps":-0.05},{"market":"US","date":"2021-06-29","symbol":"SVA","fiscalQuarterEnding":"2021/03","expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1624939200000,"reportTimeType":"","actualEps":-0.07}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"SVA\",market:\"US\",,,undefined,":[{"executeDate":"2025-07-08","recordDate":"2025-05-23","paymentDate":"2025-07-07","value":55,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"SVA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/SVA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"SVA","date":"2021-09-21","current":-4.938931,"percent":0.24257,"low":-100.201212,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"high":42.074882,"avg":0.136365,"sd":42.133061,"marketCap":642436987},"quantilePoints":[{"date":"2021-03-26","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-01","current":25.871431,"twenty":-61.668314,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-09","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-16","current":25.871431,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-23","current":5.79786,"twenty":-61.894113,"median":24.277937,"eighty":29.57901,"marketCap":639903982},{"date":"2021-04-30","current":5.82081,"twenty":-61.894113,"median":24.171596,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-07","current":5.82081,"twenty":-61.894113,"median":24.081398,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-14","current":5.82081,"twenty":-61.894113,"median":23.985687,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-21","current":5.82081,"twenty":-61.894113,"median":23.781276,"eighty":29.57901,"marketCap":642436987},{"date":"2021-05-28","current":5.82081,"twenty":-61.894113,"median":23.705864,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-04","current":5.82081,"twenty":-61.894113,"median":23.662388,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-11","current":5.82081,"twenty":-61.894113,"median":23.535556,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-18","current":5.82081,"twenty":-61.894113,"median":23.44385,"eighty":29.57901,"marketCap":642436987},{"date":"2021-06-25","current":5.82081,"twenty":-62.119913,"median":23.213593,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-02","current":5.82081,"twenty":-62.119913,"median":22.996932,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-09","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-16","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-23","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-07-30","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-06","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-13","current":5.82081,"twenty":-61.894113,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-20","current":5.82081,"twenty":-61.894113,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-08-27","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-03","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-10","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-17","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-09-24","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-01","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-08","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-15","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-22","current":5.82081,"twenty":-62.345712,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-10-29","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-11-05","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987},{"date":"2021-11-09","current":5.82081,"twenty":-62.119913,"median":22.039362,"eighty":29.57901,"marketCap":642436987}],"updateTime":1774268562075},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"SVA\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2605400557","title":"國產甲肝疫苗獨家中標阿曼兩年訂單","url":"https://stock-news.laohu8.com/highlight/detail?id=2605400557","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605400557?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 14:18","pubTimestamp":1769149080,"startTime":"0","endTime":"0","summary":"近日，科兴甲型肝炎灭活疫苗孩尔来福®独家中标阿曼2026-2027年度公费市场项目。自2022年进入阿曼市场，科兴凭借产品质量、供应时效和物流保障等优势，逐步建立可靠信誉，最终获独家供应资格。海合会六国免疫规划疫苗此前多由跨国药企供应，此次中标意味着科兴产品质量与国际履约能力获海合会国家信任，是其中东非市场重要突破。截至目前，科兴甲肝疫苗孩尔来福®已累计向全球近50个国家和地区供应超1.3亿剂次，成为全球使用最广泛的甲肝灭活疫苗之一。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123143029a6a3c30a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260123143029a6a3c30a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2605556400","title":"科興流感疫苗在阿拉伯聯合酋長國獲批註冊","url":"https://stock-news.laohu8.com/highlight/detail?id=2605556400","media":"界面","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605556400?lang=zh_tw&edition=fundamental","pubTime":"2026-01-23 14:00","pubTimestamp":1769148032,"startTime":"0","endTime":"0","summary":"1月23日，据”SINOVAC科兴”消息，近日，科兴流感疫苗正式获得阿拉伯联合酋长国卫生与预防部（MOHAP）颁发的药品注册证书。截至目前，科兴季节性流感疫苗已在全球20余个国家和地区广泛使用，累计供应量已超1.2亿剂。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012314003297a31120&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026012314003297a31120&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2605492982","title":"科興獲准維持納斯達克上市地位，需在5月11日前完成財報報送","url":"https://stock-news.laohu8.com/highlight/detail?id=2605492982","media":"澎湃新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605492982?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 21:57","pubTimestamp":1769090264,"startTime":"0","endTime":"0","summary":"昔日凭新冠疫苗走红的科兴或有机会维持纳斯达克上市地位。1月22日晚间，科兴控股生物技术有限公司（Nasq：SVA，以下简称“科兴生物”）官网发布消息称，公司已正式获得纳斯达克听证委员会批准，将继续维持在纳斯达克全球市场的上市地位。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202601223627701015.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601223627701015.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["NQmain","QQQE","GPIQ","MNQmain","QLD","JEPQ","USAW.SI","QYLG","BK4007","QYLD","PSQ","QQQY","TSYW.SI","TQQQ","QQQJ","QID","NVIW.SI","BK1147","USJW.SI","SVA","SQQQ"],"gpt_icon":1},{"id":"2605746006","title":"納斯達克批准科興維持上市地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2605746006","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605746006?lang=zh_tw&edition=fundamental","pubTime":"2026-01-22 19:14","pubTimestamp":1769080471,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["JEPQ","QYLG","PSQ","USAW.SI","QYLD","NVIW.SI","QLD","SVA","USJW.SI","MNQmain","QQQE","QID","QQQJ","GPIQ","QQQY","BK1147","QQQ","SQQQ","TSYW.SI","TQQQ","QQQM","BK4007"],"gpt_icon":0},{"id":"2593477341","title":"科興生物董事會爭鬥再起波瀾 退市危機依舊待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477341","media":"央广财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2593477341?lang=zh_tw&edition=fundamental","pubTime":"2025-12-24 21:25","pubTimestamp":1766582704,"startTime":"0","endTime":"0","summary":"央广网北京12月24日消息（记者邹煦晨）面临退市危机的科兴生物（NASDAQ:SVA），董事会争斗有了最新进展。近日，该公司在其官网披露，安提瓜高等法院作出临时裁决，SimonAnderson、付山、焦树阁、卢毓琳、裘育敏、王宇、阎焱及尹卫东组成公司的董事会履行公司董事会职权，直至2025年特别股东大会争议案（下称“股东会议争议案”）庭审。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512243600985033.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"1101424265","title":"Antigua法院發布臨時命令，授予科興生物董事會控制權，直至2025年股東大會爭議審判","url":"https://stock-news.laohu8.com/highlight/detail?id=1101424265","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1101424265?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 20:18","pubTimestamp":1765973915,"startTime":"0","endTime":"0","summary":"12月17日（路透社） - 科兴生物科技有限公司：*科兴生物：安提瓜法院发布临时命令，授予公司董事会控制权，直至2025年股东大会争议的审判*科兴生物科技有限公司 - SSM争议听证会定于2026年4月底/5月初举行  ((路透社投资者简报；电子邮箱：reutersinvestor.briefs@thomsonreuters.com))  来源日期/时间 = 2025年12月17日12:00:00.567 GMT","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"1104966625","title":"科興生物：安提瓜法院發布臨時命令，授予董事會控制權直至爭議2025年股東大會審理結束","url":"https://stock-news.laohu8.com/highlight/detail?id=1104966625","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104966625?lang=zh_tw&edition=fundamental","pubTime":"2025-12-17 20:07","pubTimestamp":1765973228,"startTime":"0","endTime":"0","summary":"科兴生物：安提瓜法院发布临时命令，授予董事会控制权直至争议2025年股东大会审理结束","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2589863895","title":"科興生物退市風暴：從「疫苗之王」到轟然坍塌","url":"https://stock-news.laohu8.com/highlight/detail?id=2589863895","media":"翠鸟资本","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589863895?lang=zh_tw&edition=fundamental","pubTime":"2025-12-04 17:25","pubTimestamp":1764840304,"startTime":"0","endTime":"0","summary":"结构性缺陷埋下祸根不可否认，科兴生物曾拥有显著优势。科兴生物拥有中国最大的病毒疫苗生产基地之一、成熟的灭活技术平台、覆盖60余国的国际分销网络。疫情期间，科兴生物90%以上收入依赖新冠疫苗，利润暴涨，但缺后续发力，后续管线如带状疱疹、RSV、手足口病疫苗进展缓慢，至今无一款重磅新药上市。同时，科兴生物的战略显得较为短视。如今，科兴生物虽仍在中国境内维持部分疫苗生产，但其国际影响力几近归零。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204173617a4cc59d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251204173617a4cc59d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2588947780","title":"2025年中國生物製劑行業政策、產業鏈、市場規模、研發支出、競爭格局及未來發展趨勢研判：已成為醫藥行業增長最快的領域之一，市場規模將達到6752億元[圖]","url":"https://stock-news.laohu8.com/highlight/detail?id=2588947780","media":"智研咨询","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588947780?lang=zh_tw&edition=fundamental","pubTime":"2025-12-03 09:22","pubTimestamp":1764724920,"startTime":"0","endTime":"0","summary":"因此，全球各国加速生物制剂创新研发，市场取得快速发展。2024年，中国生物制剂市场规模从2019年的3120亿元增长至5871亿元，预计2025年中国生物制剂市场规模将达到6752亿元，预计未来五年有望达到11491亿元。预计2030年中国生物制剂的研发支出从2017年的762亿元增长至3088亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203092512a7204081&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203092512a7204081&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1500","LU1303224171.USD","06160","LU0588546209.SGD","BK1583","LU0307460666.USD","LU1719994722.HKD","LU1969619763.USD","LU2328871848.SGD","LU1251922891.USD","02269","LU1770034418.SGD","BK1161","SVA","BK1588"],"gpt_icon":0},{"id":"2586204858","title":"科興生物陷退市危機，十年內鬥拖累經營與治理","url":"https://stock-news.laohu8.com/highlight/detail?id=2586204858","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586204858?lang=zh_tw&edition=fundamental","pubTime":"2025-11-28 15:51","pubTimestamp":1764316260,"startTime":"0","endTime":"0","summary":"11月19日，科兴生物公告称收到纳斯达克上市资格部门的退市决定函，原因在于公司未能在2025年11月11日前提交2024年年度报告。尽管公司已表示将提交听证申请以暂缓退市，但这一事件再次暴露了其长期存在的公司治理问题。　　审计机构致同会计师事务所于2025年4月辞任，直接导致年报无法按时提交。　　科兴生物的退市危机，表面上是审计机构变更与年报延迟所致，实则是长期公司治理混乱、控制权争夺与经营战略失衡的集中爆发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2025-11-28/doc-infyxwfh7408453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2586290309","title":"停牌6年後科興生物要退市","url":"https://stock-news.laohu8.com/highlight/detail?id=2586290309","media":"国际金融报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586290309?lang=zh_tw&edition=fundamental","pubTime":"2025-11-27 10:22","pubTimestamp":1764210143,"startTime":"0","endTime":"0","summary":"当地时间11月24日，科兴生物公告，公司与巴西卫生部签署了两项PDP（产品开发伙伴关系）项目，在未来10年向巴西提供总计约6000万剂水痘疫苗和狂犬疫苗，价值超7亿美元（约合50亿元人民币）。据该公司介绍，这是中国疫苗企业迄今获得的最长期、合同金额最大的一笔国际订单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511273576389669.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511273576389669.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SVA","BK4139"],"gpt_icon":0},{"id":"2585779891","title":"科興生物再觸退市紅線 治理困局拖累美股上市地位","url":"https://stock-news.laohu8.com/highlight/detail?id=2585779891","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585779891?lang=zh_tw&edition=fundamental","pubTime":"2025-11-22 22:22","pubTimestamp":1763821375,"startTime":"0","endTime":"0","summary":"纳斯达克的一纸退市函，对已停牌六年的科兴生物下达了最后通牒，其美股上市地位命悬一线。因未按期提交2024年年度报告，科兴生物（NASDAQ：SVA）于2025年11月12日收到纳斯达克上市资格部门的退市决定函。若未能在规定时间内申请听证，公司股票将于11月21日起暂停交易并启动退市程序。这是自2019年因治理问题被停牌后，科兴生物面临的第二次退市危机。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511223572077338.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511223572077338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","SVA"],"gpt_icon":0},{"id":"2584722409","title":"科興生物收到納斯達克退市通知；廣譽遠副總裁離任","url":"https://stock-news.laohu8.com/highlight/detail?id=2584722409","media":"21世纪经济报道","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584722409?lang=zh_tw&edition=fundamental","pubTime":"2025-11-20 08:06","pubTimestamp":1763597181,"startTime":"0","endTime":"0","summary":"政策动向黄果在北京调研集采中选药品质量监管工作11月18日，国家药监局党组成员、副局长黄果在北京市调研集采中选药品质量监管工作，实地走访华润双鹤药业股份有限公司，调研企业质量管理及地方药品监管部门监管情况。黄果指出，国家药监局高度重视集采药品的质量监管，在各方持续努力下，生产供应质量整体稳定可控。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511203569355255.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511203569355255.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03086","USJW.SI","NVIW.SI","USAW.SI","PSQ","TQQQ","SVA","ARTL",".IXIC","BK4007","MNQmain","QID","BK1147","QLD","SQQQ","BK4139","TSYW.SI","NQmain"],"gpt_icon":1},{"id":"2584717948","title":"科興生物收到納斯達克退市通知 公司回應：計劃進行聽證申辯會","url":"https://stock-news.laohu8.com/highlight/detail?id=2584717948","media":"每日经济新闻","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584717948?lang=zh_tw&edition=fundamental","pubTime":"2025-11-19 19:26","pubTimestamp":1763551600,"startTime":"0","endTime":"0","summary":"科兴生物更新了一则关于纳斯达克退市事项的进展。公司披露的信息显示，其于2025年11月12日收到纳斯达克股票市场有限责任公司（即“纳斯达克”）上市资格部发出的退市决定函。此决定是由于公司未能遵守纳斯达克上市规则5250(c)(1)，未能在延长期限前及时提交截至2024年12月31日财年的年度报告。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202511193568947938.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202511193568947938.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["QLD","MNQmain","NQmain","BK1147","QID","ARTL","SQQQ","SVA","PSQ","TSYW.SI","USAW.SI","USJW.SI",".IXIC","NVIW.SI","03086","TQQQ","BK4139","BK4007"],"gpt_icon":0},{"id":"2569799104","title":"科興生物人干擾素α1b吸入溶液納入突破性治療品種名單","url":"https://stock-news.laohu8.com/highlight/detail?id=2569799104","media":"北京商报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2569799104?lang=zh_tw&edition=fundamental","pubTime":"2025-09-23 17:50","pubTimestamp":1758621043,"startTime":"0","endTime":"0","summary":"北京商报讯（记者王寅浩实习记者宋雨盈）9月23日，科兴生物发布公告称，公司全资子公司深圳科兴药业有限公司自主研发的人干扰素α1b吸入溶液已被国家药品监督管理局药品审评中心纳入突破性治疗品种名单。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202509233521320417.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202509233521320417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SVA","BK4139"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":15,"code":"91000000","status":"200"}]}}